Takeda has continued its expansion in Latin America, establishing a new sales and marketing subsidiary in Peru.
Headquartered in Lima, Takeda Peru adds to the company’s existing operations in Brazil, Argentina, Mexico, Venezuela, Colombia and Ecuador.
Its latest subsidiary in the region will be led by Julio Cesar Acevedo Orrego, who was formerly marketing – promotion and sales manager for Takeda Colombia.
There he built up and headed the Takeda Sales and Marketing organisation following the company’s acquisition of Farmacol Laboratories.
Takeda Peru will focus on gastroenterology, cardiology, metabolism, oncology and respiratory diseases, but with an initial focus on just four products. These will be ulcer treatments Zurcal (pantoprazole) and Riopan (Magaldrate + Dimeticone), the anti-inflammatory Faktu (Policresulen, Cinchocaine hydrochloride) and Albothyl (Policresulen), a gynaecology product.
Norbert Oppitz, senior vice president for Latin America at Takeda, said: “The launch of our subsidiary in Peru reinforces Takeda’s position in Latin America and will enable us to meet the diverse healthcare needs of the population.
“We have an established product portfolio, which will give us a strong starting point and we look forward to launching our novel medicines into the market. This investment further demonstrates our commitment to Latin America and its growth potential.”
Eyeing regional market growth that is expected to run at a compound annual rate of 12.5 per cent until 2017, Takeda said it plans on “building a leading position in Latin America”.